Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States
SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development *platform*, powered by *machine learning* and *novel, patented algorithms* for the *quantifiable* detection of biomarkers.
The company successfully *designed specific peptides* to bind to pre-established, *proven biomarkers for Cardiovascular Diseases* and is currently developing *effective diagnostic assays*. The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving *highly accurate and fast results*.
According to the U.S. Department of Health & Human Services, a total of 697000 people died in 2020, *one person dies every 34 seconds* in the US from cardiovascular disease.
This is made possible with the product *TruHeart™*, a point-of-care assay to *diagnose Acute Coronary Syndrome *that can give *quantifiable* results within *3-5 minutes*, using a *finger-prick* sample to test for the *crucial* biomarkers, *Troponins I and T*, and *Myoglobin *(eventually expanding to *D-Dimer *and *Brain Natriuretic Peptide*). It is in the advanced stages of R&D and progressing to *global clinical trials*. It will be submitted for FDA approval and then introduced to the market upon approval.
This product could be a game-changer, allowing patients to affordably screen for this potentially deadly condition *conveniently early, in their own home*, achieving *quantifiable* results *without needing a laboratory*. This more efficiently guides patients to seek appropriate medical attention; those with prevailing heart conditions may also *regularly *monitor their condition *at home*. In comparison to industry standards, it will be *uniquely affordable*; its peptide-coated cartridges will cost *only ~USD$2*, while the quantitative electronic reader will cost *~USD$80*. This is in *contrast* to existing point-of-care devices also giving quantitative results for cardiac biomarkers, but at device costs of up to *USD$4,500, *with cartridges ranging from *USD$18-37*.
The company's Scientific Advisory Board includes prominent leaders in this field, such as *Padmashri Balram Bhargava,* former Director General Indian Council of Medical Research (ICMR). The company has scheduled *clinical trials* in five hospitals in India (including the renowned *Narayana* *Hrudayalaya*), in the process of securing a large site in the US and five sites in Europe. It is also advanced discussions with *A*Star* and *Singapore's National Heart Centre.* This is only one of many pipeline products made possible by its patented method of peptide-design. The immediate pipeline includes assays for *Prostate and Colorectal Cancers,* *Dengue, Malaria, and more.*
*About Neuome Peptides*
It specializes in using a peptide-based approach to disrupt and democratize the diagnostics industry with affordable devices, able to provide lab-quality results in a fraction of the time and at a fraction of the cost. In line with its motto, "Convergence of Science" that integrates elements of life sciences, nanotechnology, electronics, and AI/machine learning in its products. The company is aware of the cost-inefficiencies of existing diagnostic solutions, therefore, the mission is to develop accurate, efficient and affordable diagnostic solutions to prevalent global health issues.
Learn more about TruHeart™: https://neuomepeptides.com/truheart/